Grand Pharma Sets 5 June 2026 AGM; Proposes HK$0.169 Final Dividend, Director Re-elections and Bye-law Update

Bulletin Express04-29

Grand Pharmaceutical Group Limited (Grand Pharma) has issued the proxy form for its annual general meeting scheduled for 11:00 a.m. on 5 June 2026 at Unit 3302, The Center, 99 Queen’s Road Central, Hong Kong.

Key items on the agenda include:

1. Financial Statements and Dividend • Shareholders will vote on adopting the audited financial statements for the year ended 31 December 2025. • The board is recommending a final dividend of HK$0.169 per share for the same period.

2. Board Composition and Remuneration • Proposed re-elections: – Mr. Zhou Chao as Executive Director. – Mr. Hu Yebi as Independent Non-Executive Director. – Dr. Pei Geng to continue as Independent Non-Executive Director despite serving more than nine years. • The board seeks authority to determine directors’ remuneration.

3. Auditor Appointment • Renewal of HLB Hodgson Impey Cheng Limited as external auditor until the next AGM, with the board authorised to fix the audit fee.

4. Share Issuance and Repurchase Mandates • Ordinary resolutions will grant the board general mandates to issue new shares and repurchase existing shares. • An additional resolution proposes extending the issuance mandate by the number of shares repurchased.

5. Corporate Governance • A special resolution seeks shareholder approval for amendments to the existing bye-laws and adoption of new bye-laws.

Shareholders must submit proxy forms to Computershare Hong Kong Investor Services Limited no later than 48 hours before the meeting to exercise voting rights in absentia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186792552?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186792552","market":"hk","top_or_hot":-1,"title":"Grand Pharma Sets 5 June 2026 AGM; Proposes HK$0.169 Final Dividend, Director Re-elections and Bye-law Update","media":"Bulletin Express","content":"<p>Grand Pharmaceutical Group Limited (Grand Pharma) has issued the proxy form for its annual general meeting scheduled for 11:00 a.m. on 5 June 2026 at Unit 3302, The Center, 99 Queen’s Road Central, Hong Kong.</p>\n<p>Key items on the agenda include:</p>\n<p>1. Financial Statements and Dividend  \n   • Shareholders will vote on adopting the audited financial statements for the year ended 31 December 2025.  \n   • The board is recommending a final dividend of HK$0.169 per share for the same period.</p>\n<p>2. Board Composition and Remuneration  \n   • Proposed re-elections:  \n     – Mr. Zhou Chao as Executive Director.  \n     – Mr. Hu Yebi as Independent Non-Executive Director.  \n     – Dr. Pei Geng to continue as Independent Non-Executive Director despite serving more than nine years.  \n   • The board seeks authority to determine directors’ remuneration.</p>\n<p>3. Auditor Appointment  \n   • Renewal of HLB Hodgson Impey Cheng Limited as external auditor until the next AGM, with the board authorised to fix the audit fee.</p>\n<p>4. Share Issuance and Repurchase Mandates  \n   • Ordinary resolutions will grant the board general mandates to issue new shares and repurchase existing shares.  \n   • An additional resolution proposes extending the issuance mandate by the number of shares repurchased.</p>\n<p>5. Corporate Governance  \n   • A special resolution seeks shareholder approval for amendments to the existing bye-laws and adoption of new bye-laws.</p>\n<p>Shareholders must submit proxy forms to Computershare Hong Kong Investor Services Limited no later than 48 hours before the meeting to exercise voting rights in absentia.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grand Pharma Sets 5 June 2026 AGM; Proposes HK$0.169 Final Dividend, Director Re-elections and Bye-law Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrand Pharma Sets 5 June 2026 AGM; Proposes HK$0.169 Final Dividend, Director Re-elections and Bye-law Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-29 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Grand Pharmaceutical Group Limited (Grand Pharma) has issued the proxy form for its annual general meeting scheduled for 11:00 a.m. on 5 June 2026 at Unit 3302, The Center, 99 Queen’s Road Central, Hong Kong.</p>\n<p>Key items on the agenda include:</p>\n<p>1. Financial Statements and Dividend  \n   • Shareholders will vote on adopting the audited financial statements for the year ended 31 December 2025.  \n   • The board is recommending a final dividend of HK$0.169 per share for the same period.</p>\n<p>2. Board Composition and Remuneration  \n   • Proposed re-elections:  \n     – Mr. Zhou Chao as Executive Director.  \n     – Mr. Hu Yebi as Independent Non-Executive Director.  \n     – Dr. Pei Geng to continue as Independent Non-Executive Director despite serving more than nine years.  \n   • The board seeks authority to determine directors’ remuneration.</p>\n<p>3. Auditor Appointment  \n   • Renewal of HLB Hodgson Impey Cheng Limited as external auditor until the next AGM, with the board authorised to fix the audit fee.</p>\n<p>4. Share Issuance and Repurchase Mandates  \n   • Ordinary resolutions will grant the board general mandates to issue new shares and repurchase existing shares.  \n   • An additional resolution proposes extending the issuance mandate by the number of shares repurchased.</p>\n<p>5. Corporate Governance  \n   • A special resolution seeks shareholder approval for amendments to the existing bye-laws and adoption of new bye-laws.</p>\n<p>Shareholders must submit proxy forms to Computershare Hong Kong Investor Services Limited no later than 48 hours before the meeting to exercise voting rights in absentia.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00512","symbol_name":"远大医药","start_time":0,"source_url":"","article_id":"1186792552","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186792552","pubTimestamp":1777465418,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Grand Pharmaceutical Group Limited (Grand Pharma) has issued the proxy form for its annual general meeting scheduled for 11:00 a.m. on 5 June 2026 at Unit 3302, The Center, 99 Queen’s Road Central,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00512":"远大医药"},"translate_title":"远大医药定于2026年6月5日召开年度股东大会；建议派发末期股息0.169港元、重选董事及更新公司细则","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":1},"content_text":"Grand Pharmaceutical Group Limited (Grand Pharma) has issued the proxy form for its annual general meeting scheduled for 11:00 a.m. on 5 June 2026 at Unit 3302, The Center, 99 Queen’s Road Central, Hong Kong.\nKey items on the agenda include:\n1. Financial Statements and Dividend  \n   • Shareholders will vote on adopting the audited financial statements for the year ended 31 December 2025.  \n   • The board is recommending a final dividend of HK$0.169 per share for the same period.\n2. Board Composition and Remuneration  \n   • Proposed re-elections:  \n     – Mr. Zhou Chao as Executive Director.  \n     – Mr. Hu Yebi as Independent Non-Executive Director.  \n     – Dr. Pei Geng to continue as Independent Non-Executive Director despite serving more than nine years.  \n   • The board seeks authority to determine directors’ remuneration.\n3. Auditor Appointment  \n   • Renewal of HLB Hodgson Impey Cheng Limited as external auditor until the next AGM, with the board authorised to fix the audit fee.\n4. Share Issuance and Repurchase Mandates  \n   • Ordinary resolutions will grant the board general mandates to issue new shares and repurchase existing shares.  \n   • An additional resolution proposes extending the issuance mandate by the number of shares repurchased.\n5. Corporate Governance  \n   • A special resolution seeks shareholder approval for amendments to the existing bye-laws and adoption of new bye-laws.\nShareholders must submit proxy forms to Computershare Hong Kong Investor Services Limited no later than 48 hours before the meeting to exercise voting rights in absentia.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186792552","isCrawlerRequest":true}